Inactive Instrument

Sprint Bioscience AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- - Intraday chart for Sprint Bioscience AB

Financials

Sales 2024 * 118M 10.81M 0 902M Sales 2025 * 199M 18.23M 0 1.52B Capitalization 92.86M 8.51M 0 710M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 0.04 x
Net cash position 2024 * 88.2M 8.08M 0 674M Net cash position 2025 * - 0 - 0 EV / Sales 2025 * 0.47 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 47.2%
More Fundamentals * Assessed data
Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sprint Bioscience Licenses the Vada Program to Day One Biopharmaceuticals CI
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Vivesto Names Sprint Bioscience Boss as New CEO; Shares Down 6% MT
Sprint Bioscience Reports Novel AMLarget Proteins in Ongoing Collaboration CI
Sprint Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Sprint Bioscience Launches NIMA at BIO International CI
Sprint Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021 CI
More news
Managers TitleAgeSince
Chief Executive Officer 40 01/23/01
Founder 53 01/09/01
Director of Finance/CFO 51 01/11/01
Members of the board TitleAgeSince
Director/Board Member 68 01/20/01
Chairman 56 01/21/01
Director/Board Member 48 01/19/01
More insiders
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
More about the company